We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oncorus Inc | NASDAQ:ONCR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.12055 | 0.13 | 0.091 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 15, 2022 |
ONCORUS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-39575 |
47-3779757 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
50 Hampshire Street Suite 401 |
|
|||
Cambridge, Massachusetts |
|
02139 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (857) 320-6400 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
Common Stock, $0.0001 par value per share |
|
ONCR |
|
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 15, 2022, John McCabe notified Oncorus, Inc. (the "Company") of his intention to resign as Chief Financial Officer and Treasurer of the Company, effective April 1, 2022, to pursue an opportunity with a private company. Mr. McCabe's resignation does not result from any disagreement with the Company on any matter relating to the Company's operations, policies and practices. Theodore (Ted) Ashburn, the Company's Chief Executive Officer, commented, "John has played a key role in Oncorus' growth, including through our Series B financing and the closing of our IPO, but we understand his interest in pursuing this new opportunity. On behalf of the entire company, we thank and wish him the very best."
In connection with Mr. McCabe's resignation, the Company and Mr. McCabe intend to enter into a Consulting Agreement (the "McCabe Agreement") pursuant to which, among other things, following April 1, 2022, Mr. McCabe will provide advisory services to the Company for a period of up to six months (the "Advisory Period"). As consideration for Mr. McCabe's advisory services, Mr. McCabe will be paid an hourly rate and his outstanding equity awards will continue to vest during the Advisory Period.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
ONCORUS, INC. |
|
|
|
|
Date: |
March 18, 2022 |
By: |
/s/ Ted Ashburn |
|
|
|
Theodore (Ted) Ashburn, M.D., Ph.D. |
1 Year Oncorus Chart |
1 Month Oncorus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions